Celtaxsys, is a biopharmaceutical company, engages in developing and testing drug compounds for treating cancer, and inflammatory and autoimmune diseases. Its technology manipulates immune cell migration as a treatment for cancer, inflammation, and organ/tissue rejection. The company's drug compounds are designed to block the protective mechanisms created by certain tumors to prevent attack by immune system cells.

Patents 102show all

  • 32
    A61K - Preparations for medical, dental, or toilet purposes
  • 16
    C07K - Peptides
  • 10
    Y02A - Technologies for adaptation to climate change
  • 9
    G01N - Investigating or analysing materials by determining their chemical or physical properties
  • 7
    C12N - Microorganisms or enzymes
  • 1
    A61L - Methods or apparatus for sterilising materials or objects in general
  • 1
    C12Q - Measuring or testing processes involving enzymes, nucleic acids or microorganisms

Clinical Trials 10show all

6Phase 24Phase 1

SEC Filings show all


4
D

Contact Information

ATDC Biosciences Center, 0390 311 Ferst Drive
Atlanta, GA 30332
United States

Overview

Total FundingEmployeesLast Funding DateStatus
$60,162,38611-502018-01-08Operating

Crunchbase Investment Rounds

DateAmountRoundValuationLead InvestorOther Investors
2010-10-27$4,231,386Series C
2018-01-08Series EInvusLumira Ventures, Masters Capital Management, RMI Partners, Domain Associates, Georgia Research Alliance
2008-05-27$3,700,000Series BMasters Capital Management
2015-06-08$45,000,000Series DDomain AssociatesLumira Ventures, Masters Capital Management, GRA Venture Fund, LLC, RMI Partners
2005-07-25$5,191,000Series AMasters Capital Management
2009-05-07$2,040,000Debt Financing

SEC Form D Funding Events

DateOfferedSoldType
2010-10-29$10,653,500$4,231,386Equity
2009-05-07$5,000,000$2,040,000Debt
2008-05-19Unknown Unknown Other (Paper Filing)

Key Executives

  • William P. Reddick
    Executive Officer, Director
  • Ralph A. Grosswald
    Executive Officer
  • Michael Hanley
    Director
  • Jan M. Lodal
    Director
  • Michael W. Masters
    Director
  • Matthew S. Dontzin
    Director
  • Eric Springman
    Executive Officer